share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股sec公告 ·  06/18 07:02
Moomoo AI 已提取核心信息
On June 17, 2024, Clene Inc. presented a poster at the 2024 ENCALS Meeting, detailing clinical results from the HEALEY ALS Platform Trial open label extension for amyotrophic lateral sclerosis (ALS) treatment with CNM-Au8. The poster, referred to as Exhibit 99.1, was furnished as part of Clene's Form 8-K current report but is not considered filed under the Securities Exchange Act nor incorporated by reference into any of Clene's filings. Additionally, on June 18, 2024, Clene issued a press release, filed as Exhibit 99.2, announcing the presentation of extended survival data through 3.5 years and new neurofilament light (NfL) responder results from the same trial at the ENCALS Meeting.
On June 17, 2024, Clene Inc. presented a poster at the 2024 ENCALS Meeting, detailing clinical results from the HEALEY ALS Platform Trial open label extension for amyotrophic lateral sclerosis (ALS) treatment with CNM-Au8. The poster, referred to as Exhibit 99.1, was furnished as part of Clene's Form 8-K current report but is not considered filed under the Securities Exchange Act nor incorporated by reference into any of Clene's filings. Additionally, on June 18, 2024, Clene issued a press release, filed as Exhibit 99.2, announcing the presentation of extended survival data through 3.5 years and new neurofilament light (NfL) responder results from the same trial at the ENCALS Meeting.
2024年6月17日,Clene公司在2024年ENCALS会议上展示了“HEALEY ALS Platform Trial”开放标签延期试验的临床结果,用于治疗肌萎缩性侧索硬化症(ALS)的CNM-Au8。海报,被称为展品99.1,作为Clene的8-K表格的一部分提供,但不被认为是根据证券交易法文件或并入任何Clene的文件中的内容。此外,2024年6月18日,Clene发布了新闻稿(作为展品99.2),宣布了同一试验中经过3.5年的扩展生存数据和新的神经丝轻链(NfL)反应器的结果在ENCALS会议上亮相。
2024年6月17日,Clene公司在2024年ENCALS会议上展示了“HEALEY ALS Platform Trial”开放标签延期试验的临床结果,用于治疗肌萎缩性侧索硬化症(ALS)的CNM-Au8。海报,被称为展品99.1,作为Clene的8-K表格的一部分提供,但不被认为是根据证券交易法文件或并入任何Clene的文件中的内容。此外,2024年6月18日,Clene发布了新闻稿(作为展品99.2),宣布了同一试验中经过3.5年的扩展生存数据和新的神经丝轻链(NfL)反应器的结果在ENCALS会议上亮相。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息